Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning
The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
Drugs that modulate serotonin (5-HT) synaptic concentrations impact neurogenesis and hippocampal (HPC)-dependent learning. The primary objective is to determine the extent to which psilocybin (PSOP) modulates neurogenesis and thereby affects acquisition and extinction of HPC-dependent trace fear conditioning. PSOP, the 5-HT2A agonist 25I-NBMeO and the 5-HT2A/C antagonist ketanserin were administered via an acute intraperitoneal injection to mice. Trace fear conditioning was measured as the amount of time spent immobile in the presence of the conditioned stimulus (CS, auditory tone), trace (silent interval) and post-trace interval over 10 trials. Extinction was determined by the number of trials required to resume mobility during CS, trace and post-trace when the shock was not delivered. Neurogenesis was determined by unbiased counts of cells in the dentate gyrus of the HPC birth-dated with BrdU co-expressing a neuronal marker. Mice treated with a range of doses of PSOP acquired a robust conditioned fear response. Mice injected with low doses of PSOP extinguished cued fear conditioning significantly more rapidly than high-dose PSOP or saline-treated mice. Injection of PSOP, 25I-NBMeO or ketanserin resulted in significant dose-dependent decreases in number of newborn neurons in hippocampus. At the low doses of PSOP that enhanced extinction, neurogenesis was not decreased, but rather tended toward an increase. Extinction of "fear conditioning" may be mediated by actions of the d…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This may explain why they have demonstrated efficacy in many preclinical rodent behavioral tests involving PFC circuitry including the forced swim test and fear extinction learning (151, 194–197).”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [196]
In the citing paper
“At a biological level, psilocybin induced a dose-dependent effect on neurogenesis, with a low dose increasing, and a high dose decreasing neurogenesis (62).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [62]
In the citing paper
“Psilocybin-treated mice exhibited increased extinction compared to saline-treated controls for all doses, indicating a quicker learning response to fear (62).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [62]
In the citing paper
“Mice (n = 6) that were administered a single, low dose of psilocybin (0.1 mg/kg, i.p) showed a non-significant increase in proliferation of hippocampal progenitor cells 14 days later.”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [62]
In the citing paper
“Behavioral effects of psilocybin demonstrated a dose-independent stimulation of fear extinction”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [62]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus
van Praag, H., Kempermann, G., & Gage, F. H. (1999) · Nature Neuroscience · doi:10.1038/6368 · Cited by 3,880
Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats
Altman, J., & Das, G. D. (1965) · Journal of Comparative Neurology · doi:10.1002/cne.901240303 · Cited by 3,592 · cited 1×
“Neurogenesis occurs throughout the life span in the adult brain, the subventricular zone (SVZ) and the subgranular zone (SGZ) in the DG (Altman 1962, 1969; Altman and Das 1965).”
BackgroundA review of central 5-HT receptors and their function
Barnes, N. M., & Sharp, T. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00010-6 · Cited by 3,161
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111
Functional neurogenesis in the adult hippocampus
van Praag, H., Schinder, A. F., Christie, B. R., Toni, N., Palmer, T. D., & Gage, F. H. (2002) · Nature · doi:10.1038/4151030a · Cited by 2,853
Modality-Specific Retrograde Amnesia of Fear
Kim, J. J., & Fanselow, M. S. (1992) · Science · doi:10.1126/science.1585183 · Cited by 2,483
Learning enhances adult neurogenesis in the hippocampal formation
Gould, E., Beylin, A., Tanapat, P., Reeves, A., & Shors, T. J. (1999) · Nature Neuroscience · doi:10.1038/6365 · Cited by 2,157 · cited 1×
“Evidence suggests that performance on HPC-dependent learning tasks is influenced by neurogenesis in the DG of the HPC (Van et al. 2002; Gould et al. 1999a, b; Nilsson et al. 1999; Shors et al. 2001, 2002).”
BackgroundNibuya, M., Morinobu, S., & Duman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07539.1995 · Cited by 2,109 · cited 1×
“Chronic administration of 5-HT agonists (including SSRIs) upregulates BDNF mRNA expression in the HPC (Nibuya et al. 1995, 1996).”
BackgroundNeurogenesis in the adult is involved in the formation of trace memories
Shors, T. J., Miesegaes, G., Beylin, A., Zhao, M., Rydel, T., & Gould, E. (2001) · Nature · doi:10.1038/35066584 · Cited by 2,023
The Emotional Brain, Fear, and the Amygdala
LeDoux, J. (2003) · Cellular and Molecular Neurobiology · doi:10.1023/a:1025048802629 · Cited by 1,818 · cited 1×
“the dentate gyrus (DG), hilus, cornu ammonis (CA) 1 and CA3 and are colocalized on GABAergic neurons, pyramidal and granular cells (Luttgen et al. 2004; Morilak et al. 1993, 1994; Pompeiano et al. 1994; Shen and Andrade 1998; Cornea-Hebert et al. 1999).”
Background
Cited by
Items 101–200 of 279
How do serotonergic psychedelics treat depression: The potential role of neuroplasticity
Artin, H., Zisook, S., & Ramanathan, D. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i6.201 · Cited by 33
A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics
Banushi, B., & Polito, V. (2023) · Biology · doi:10.3390/biology12111380 · Cited by 37
Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms
Garcia‐Romeu, A., Darcy, S., Jackson, H., White, T., & Rosenberg, P. B. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_267 · Cited by 36
“These mechanisms include promotion of structural and functional neuroplasticity (Catlow et al. 2013; Lima da Cruz et al. 2018; Ly et al. 2018), post-acute changes in key signaling pathways such as brain-derived neurotrophic factor (BDNF) (Hutten et al. 2021; Ly et al. 2018), anti-inflammatory…”
BackgroundAnimal Behavior in Psychedelic Research
Odland, A. U., Kristensen, J. L., & Andreasen, J. T. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000590 · Cited by 32
Ching, T. H. W., Grazioplene, R., Bohner, C., Kichuk, S. A., DePalmer, G., D’Amico, E., Eilbott, J., Jankovsky, A., Burke, M., Hokanson, J., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1178529 · Cited by 29
“Additionally, a preclinical study showed that psilocybin facilitates acute extinction of classically conditioned fear responses and increases hippocampal neurogenesis (40).”
BackgroundIs Adult Hippocampal Neurogenesis Really Relevant for the Treatment of Psychiatric Disorders?
Carli, M., Aringhieri, S., Kolachalam, S., Longoni, B., Grenno, G., Rossi, M., Gemignani, A., Fornai, F., Maggio, R., & Scarselli, M. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200818194948 · Cited by 34
“Like ketamine, low doses of the psychedelic drug psilocybin also tend to increase hippocampal neurogenesis [166].”
BackgroundKelly, T. J., Bonniwell, E. M., Mu, L., Liu, X., Hu, Y., Friedman, V., Yu, H., Su, W., McCorvy, J. D., & Liu, Q.-S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01744-8 · Cited by 35
“Mice that received 4-OH-DiPT before extinction training spent less time freezing during cue presentations, which could be due to enhanced inhibition of BLA principal neurons.”
A multi-institutional investigation of psilocybin’s effects on mouse behavior
Lu, O., White, K., Raymond, K. B., Liu, C. J., Klein, A. S., Green, N., Vaillancourt, S., Gallagher, A. J., Shindy, L., Li, A., et al. (2026) · Nature Neuroscience · doi:10.1101/2025.04.08.647810 · Cited by 34
Werle, I., Nascimento, L. M. M., dos Santos, A. L. A., Soares, L. A., SANTOS, R. G. D., Hallak, J. E. C., & Bertoglio, L. J. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16315 · Cited by 34
“The latter drugs also facilitate aversive memory extinction in rodents (Catlow et al., 2013; Moliner et al., 2023).”
BackgroundPsilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles
Rogers, S. A., Heller, E. A., & Corder, G. F. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-01964-9 · Cited by 30
“First, we aimed to expand on the results in Catlow et al. 2013, where the authors showed that mice injected with 1.0 mg/kg of psilocybin 24 hours before training both acquired and extinguished TFC more rapidly and completely than sa-line-administered mice 76 .”
InfluentialThe mechanistic divide in psychedelic neuroscience: An unbridgeable gap?
Barksdale, B. R., Doss, M. K., Fonzo, G. A., & Nemeroff, C. B. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00322 · Cited by 28
“After psychedelic exposure, there are observable changes in structural markers of neural plasticity, encompassing enhanced synaptogenesis and dendritic growth, with less robust evidence for neurogenesis in the dentate gyrus of the hippocampus [43 – 45].”
BackgroundPsilocybin for the treatment of Alzheimer’s disease
Zheng, S., Ma, R., Yang, Y., & Li, G. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1420601 · Cited by 28
Psychedelics for the Treatment of Obsessive–Compulsive Disorder: Efficacy and Proposed Mechanisms
Collins, H. M. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae057 · Cited by 29
Rapid, biochemical tagging of cellular activity history in vivo
Zhang, R., Anguiano, M., Aarrestad, I. K., Lin, S., Chandra, J., Vadde, S. S., Olson, D. E., & Kim, C. K. (2024) · Nature Methods · doi:10.1038/s41592-024-02375-7 · Cited by 25
Altered states of consciousness and creativity
Prochazkova, L., & Hommel, B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816400-6.00006-7 · Cited by 28
Molecular and Medical Aspects of Psychedelics
Wojtas, A., & Gołembiowska, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010241 · Cited by 27
“Furthermore, psilocybin/psilocin facilitated fear extinction in rats [106,107].”
BackgroundSun, L., Cui, K., Xing, F., & Liu, X. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112375 · Cited by 27
Kolasa, M., Nikiforuk, A., Korlatowicz, A., Solich, J., Potasiewicz, A., Dziedzicka‐Wasylewska, M., Bugno, R., Hogendorf, A. S., Bojarski, A. J., & Faron‐Górecka, A. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06644-3 · Cited by 29
Werle, I., & Bertoglio, L. J. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105899 · Cited by 26
Gattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.16017 · Cited by 28
“Finally, Catlow et al. (2013) found that at 0.1 mg/kg (i.p.) psilocybin trended to increase neuronal cell proliferation in the hippocampus of fear-conditioned mice.”
InfluentialSong, S., Kong, X., Acosta, S., Sava, V., Borlongan, C. V., & Sanchez‐Ramos, J. (2016) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-150607 · Cited by 27
Self-citationHow Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder
Doss, M. K., DeMarco, A., Dunsmoor, J. E., Cisler, J. M., Fonzo, G. A., & Nemeroff, C. B. (2024) · Drugs · doi:10.1007/s40265-024-02106-4 · Cited by 27
“Other studies found that 24–48 h after drug administration, the post-acute effects of psilocybin in mice [102], DMT in rats [103], and the psychedelic 2,5-dimethoxy-4-iodoampheta-mine (DOI) in mice [104] did not impact trace, auditory, or contextual fear conditioning, respectively.”
InfluentialCan Psychedelic Drugs Attenuate Age-Related Changes in Cognition and Affect?
Aday, J. S., Bloesch, E. K., & Davoli, C. C. (2019) · Journal of Cognitive Enhancement · doi:10.1007/s41465-019-00151-6 · Cited by 27
The psychedelic renaissance: the next trip for psychiatry?
Kelly, J. R., Baker, A., Babiker, M., Burke, L., Brennan, C., & O’Keane, V. (2022) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2019.39 · Cited by 21
“At the cellular level, psy-chedelics act as ‘ psychoplastogens ’ , a relatively new class of fast-acting therapeutics capable of rapidly promoting structural and functional neural plasticity (Catlow et al .”
Glavonic, E., Mitić, M., & Adžić, M. (2022) · Journal of Neuroscience Research · doi:10.1002/jnr.25017 · Cited by 24
“In addition, studies have shown that blockade of 5- HT2A receptors disrupts extinctionaugmenting effects of MDMA (Young et al., 2017) and classical psychedelics psilocybin (Catlow et al., 2013) and 1- (2,5- dimethoxy- 4- io dophenyl)- 2- aminopropane (DOI; de la Fuente Revenga et al., 2021).”
BackgroundInfluentialHaniff, Z. R., Bocharova, M., Mantingh, T., Rucker, J., Velayudhan, L., Taylor, D. M., Young, A. H., Aarsland, D., Vernon, A. C., & Thuret, S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108641 · Cited by 22
“Notably, higher doses of 0.5 mg/kg and 1 mg/kg psilocybin decreased BrdU+ neural progenitor cell survival in a dose-dependent manner, the effects of which were blocked by non-selective 5-HT receptor (5-HTR) antagonist, ketanserin (Catlow et al., 2013).”
InfluentialHarari, R., Chatterjee, I., Getselter, D., & Elliott, E. (2024) · iScience · doi:10.1016/j.isci.2024.109686 · Cited by 21
Mount, R. A., Hansen, K., Sridhar, S., Mohammed, A., Abdulkerim, M., Kessel, R. M., Nazer, B., Gritton, H. J., & Han, X. (2021) · eLife · doi:10.7554/elife.56491 · Cited by 23
Vorobyeva, N. S., & Kozlova, A. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.927984 · Cited by 24
“By modulating glutamatergic neurotransmission, psilocybin can affect the brain’s reward system, increasing cognitive and emotional control, which are the basis for reducing addictive behaviours (Catlow et al., 2013; Michael, 2013; Dos Santos et al., 2016).”
BackgroundGermann, C. B. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109406 · Cited by 22
Awake or Sleeping? Maybe Both… A Review of Sleep-Related Dissociative States
Sodré, M. E. J., Wießner, I., Irfan, M., Schenck, C. H., & Mota-Rolim, S. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123876 · Cited by 23
“Therefore, psychedelics might aid the fear memory extinction by reactivation, modulation, and reconsolidation, a notion supported by animal studies [171,172].”
ResultArmstrong, M., Castellanos, J. P., & Christie, D. (2024) · Frontiers in Pain Research · doi:10.3389/fpain.2024.1346053 · Cited by 24
Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review
da Cruz, R. V. L., Leão, R. N., & Moulin, T. C. (2024) · Molecular Medicine · doi:10.1186/s10020-024-01013-4 · Cited by 22
“Table 5 ) (Catlow et al., 2013).”
InfluentialJager, J. E. D., Boesjes, R., Roelandt, G. H. J., Koliaki, I., Sommer, I. E., Schoevers, R. A., & Nuninga, J. O. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105796 · Cited by 21
Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis
Caspani, G., Ruffell, S., Tsang, W., Netzband, N., Rohani-Shukla, C., Swann, J. R., & Jefferies, W. A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107338 · Cited by 21
“…more complex: psilocybin increases hippocampal neurogenesis at low doses (0.1 mg/kg), but decreases it at higher doses (1.0 mg/kg) [33]; however, repeated administration of a high dose (1.5 mg/kg weekly for 4 weeks) was reported to increase the formation of new neurons in the dorsal ganglia [33].”
InfluentialCatlow, B. J., Jalloh, A., & Sanchez‐Ramos, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800212-4.00077-7 · Cited by 21
Self-citationPsychoactive Drugs in the Management of Post Traumatic Stress Disorder: A Promising New Horizon
Elsouri, K. N., Kalhori, S., Colunge, D., Grabarczyk, G., Hanna, G., Carrasco, C., Espino, A. A., Francisco, A., Borosky, B., Bekheit, B., et al. (2022) · Cureus · doi:10.7759/cureus.25235 · Cited by 21
Pouyan, N., Khankahdani, Z. H., Sisi, F. Y., Lee, Y. L., Rosenblat, J. D., Teopiz, K. M., Lui, L. M. W., Subramaniapillai, M., Lin, K., Nasri, F., et al. (2022) · CNS Drugs · doi:10.1007/s40263-022-00944-y · Cited by 18
Evidence on the impairing effects of Ayahuasca on fear memory reconsolidation
Daneluz, D. M., Sohn, J. M. B., Silveira, G. D. O., Yonamine, M., & Stern, C. A. J. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06217-2 · Cited by 22
“In addition, either DMT or the β-carbolines when tested isolated and depending on the dose reduce fear responses (Catlow et al. 2013; Cameron et al. 2019; Libânio et al. 2021).”
BackgroundResultInfluentialMarchetta, E., Mancini, G. F., Morena, M., & Campolongo, P. (2022) · Current Neuropharmacology · doi:10.2174/1570159x21666221207162750 · Cited by 20
“However, the effects on empathy [226], mindfulness related capacities [227], avoidance, acceptance and connectedness [228], long-term openness [229, 230], and emotional break-through experiences [231] along with preclinical studies, demonstrating an enhancing effect on fear memory extinction [232, 233], should determi…”
BackgroundNatural Psychoplastogens As Antidepressant Agents
Benko, J., & Vranková, S. (2020) · Molecules · doi:10.3390/molecules25051172 · Cited by 19
“However, both substances have been shown to generally facilitate the extinction of fear conditioned by a cue, but not by context, which may have been mediated by its action on the amygdala [60,61].”
BackgroundPsilocybin reduces grooming in the SAPAP3 knockout mouse model of compulsive behaviour
Gattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110202 · Cited by 17
Psychedelic science in post-COVID-19 psychiatry
Kelly, J. R., Crockett, M. T., Alexander, L., Haran, M., Baker, A., Burke, L., Brennan, C., & O’Keane, V. (2021) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2020.94 · Cited by 16
“…2019, Meinhardt et al. 2020), preclinical data have shown that serotonergic psychedelics, including psilocybin, can induce hippocampal neurogenesis (Catlow et al. 2013, Morales-Garcia et al. 2017, Vaidya et al. 1997), promote dendritic spine growth and stimulate synapse formation in the prefrontal…”
BackgroundTherapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A literature review
Fonseka, L. N., & Woo, B. K. P. (2023) · World Journal of Psychiatry · doi:10.5498/wjp.v13.i5.182 · Cited by 15
Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders
Heresco‐Levy, U., & Lerer, B. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02312-8 · Cited by 15
“Furthermore, the increase in neurogenesis was accompanied by extinction of conditioned fear related behaviors [32].”
Huang, S., Liu, X., Li, Z., Si, Y., Yang, L., Deng, J., Luo, Y., Xue, Y.-X., & Lü, L. (2024) · Neuroscience Bulletin · doi:10.1007/s12264-024-01294-z · Cited by 16
“Interestingly, it has been reported that some alkaloids yield enhanced extinction; this should be explored as a potential method of optimizing the MRUP [175–177].”
Microdosing psychedelics as cognitive and emotional enhancers.
Rifkin, B. D., Maraver, M. J., & Colzato, L. S. (2020) · Psychology of Consciousness Theory Research and Practice · doi:10.1037/cns0000213 · Cited by 16
Neurotoxicological profile of the hallucinogenic compound 25I-NBOMe
Herian, M., Wojtas, A., Maćkowiak, M., Wawrzczak‐Bargieła, A., Solarz, A., Bysiek, A., Madej, K., & Gołembiowska, K. (2022) · Scientific Reports · doi:10.1038/s41598-022-07069-8 · Cited by 16
Hosein, M., Reid, M. J., Walser, S. A., Charney, S., Fonzo, G. A., Lewis, B. R., Yaden, D. B., Suppes, T. M., Cordner, Z. A., & Barrett, F. S. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103517 · Cited by 16
“For example, psilocybin has been shown to promote neuroplasticity via hippocampal neurogenesis, 16 medial prefrontal cortex (PFC) dendritogenesis, 17 and rapid induction of neuroplasticity-related gene expression in the PFC and hippocampus.”
Schmid, Y., & Bershad, A. K. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.02.001 · Cited by 23
“Likewise, psilocybin in mice decreased cued fear conditioning, promoted neurogenesis, and enhanced hippocampal neuroplasticity (112,113).”
BackgroundPresent and future of metabolic and metabolomics studies focused on classical psychedelics in humans
Madrid-Gambín, F., Fabregat‐Safont, D., Gomez‐Gómez, À., Olesti, E., Mason, N. L., Ramaekers, J. G., & Pozo, Ó. J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115775 · Cited by 16
“…mental health disorders, including depression, anxiety, substance use disorders, obsessive-compulsive disorder, post-traumatic stress disorder, [20 – 35] The use of psychedelics has also been suggested as a promising tool for a better understanding of the physiopathology of mental illness…”
Neurobiology of the Effects of Psilocybin in Relation to Its Potential Therapeutic Targets
Tylš, F., Páleníček, T., & Horáček, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800212-4.00073-x · Cited by 15
5-Methoxy-N,N-dimethyltryptamine: An Ego-Dissolving Endogenous Neurochemical Catalyst of Creativity
Germann, C. B. (2019) · Activitas Nervosa Superior · doi:10.1007/s41470-019-00063-y · Cited by 17
Utility of preclinical models in the study of psilocybin – A comprehensive review
Pedicini, M., & Cordner, Z. A. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105046 · Cited by 15
Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder
Miller, C., & Zoladz, P. R. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.124.002237 · Cited by 13
Dong, L., Bao, H.-L., Zhang, Y., Liu, Y., Zhang, G., & An, F.-M. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.06.023 · Cited by 13
Retractedvan den Berg, M., Magaraggia, I., Schreiber, R., Hillhouse, T. M., & Porter, J. H. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06106-8 · Cited by 13
Meccia, J., Lopez, J., & Bagot, R. C. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06297-0 · Cited by 14
“) may facilitate later extinction of a fear memory without altering the initial fear association (Catlow et al. 2013).”
Background25X-NBOMe compounds – chemistry, pharmacology and toxicology. A comprehensive review
Herian, M., & Świt, P. (2023) · Critical Reviews in Toxicology · doi:10.1080/10408444.2023.2194907 · Cited by 12
“The first preclinical study about 25I-NBOMe toxicity showed a reduction in the number of BrdU-positive cells and BrdU-labeled neurons in mice hippocampus (HP) after administration of 25I-NBOMe (previously called 25I-NBMeO) at doses 0.1, 0.3 and 1mg/kg (Catlow et al. 2013).”
BackgroundInfluentialPsychoactive substances 25H-NBOMe and 25H-NBOH induce antidepressant-like behavior in male rats
Ferri, B. G., Novais, C. O., Bonani, R. S., de Barros, W. A., de Fátima, Â., Vilela, F. C., & Giusti‐Paiva, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175926 · Cited by 13
Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa
Rodan, S.-C., Aouad, P., McGregor, I. S., & Maguire, S. (2021) · OBM Neurobiology · doi:10.21926/obm.neurobiol.2102102 · Cited by 13
“Mice injected with low doses of psilocybin exhibited facilitated extinction of classically conditioned fear responses [101].”
BackgroundDhiman, A., Mehan, S., Khan, Z., Tiwari, A., Gupta, G. D., & Narula, A. S. (2024) · Current Gene Therapy · doi:10.2174/0115665232316708240828063527 · Cited by 15
Classic psychedelics as therapeutics for psychiatric disorders
Nichols, C. D., & Hendricks, P. S. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00049-9 · Cited by 18
Rahbarnia, A., Li, Z., & Fletcher, P. J. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06474-9 · Cited by 13
“Some (Quednow et al. 2012; Catlow et al. 2013), but not all (Carter et al. 2005; Hesselgrave et al. 2021), effects of psilocybin are blocked by 5-HT 2A receptor antagonists.”
The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine
Park, D., Lee, G., Lee, W.-G., Kim, B. S., Lee, Y., & Kim, J. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03100-2 · Cited by 14
VanderZwaag, B., Garcia‐Romeu, A., & García-Barrera, M. A. (2024) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253241264812 · Cited by 11
Vargas-Pérez, H., Grieder, T. E., & van der Kooy, D. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2033889 · Cited by 11
“For example, intraperitoneal administration of psilocybin increase neural plasticity in the hippocampus (Catlow et al. 2013) and frontal cortical pyramidal neurons (Raval et al. 2021; Shao et al. 2021), and enhances the extinction of aversive motivation related to fear conditioning in rodents.”
BackgroundXu, S., Xu, D., Wen, L. G., Zhu, C., Yang, Y., Han, S., & Guan, P. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s270379 · Cited by 11
Theranostic pharmacology in PTSD: Neurobiology and timing
Koek, R. J., & Luong, T. N. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.12.001 · Cited by 10
Biological embedding of early trauma: the role of higher prefrontal synaptic strength
Tamman, A. J. F., Jiang, L., Averill, C. L., Mason, G. F., Averill, L. A., & Abdallah, C. G. (2023) · European Journal of Psychotraumatology · doi:10.1080/20008066.2023.2246338 · Cited by 9
Prochazkova, L., Marschall, J., van Elk, M., Rifkin, B. D., Schon, N. R., Fiacchino, D., Fejer, G., Kuchař, M., & Hommel, B. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110732 · Cited by 10
“…improved associative and reversal learning (Aloyo et al., 2001; Bou-lougouris et al., 2008, 2008; Zhang and Stackman, 2015), and increased neuroplasticity (Catlow et al., 2013; Hutten et al., 2020) — all of which may theoretically contribute to improved divergent thinking and creative output.”
Kamińska, K., Świt, P., & Małek, K. (2020) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaa022 · Cited by 11
García‐Cabrerizo, R., Beruete-Fresnillo, I., Bergas-Cladera, P., & García-Fuster, M. J. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118720 · Cited by 9
Cassiano, L. M. G., Oliveira, M. D. S., de Barros, W. A., de Fátima, Â., & Coimbra, R. S. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17720 · Cited by 8
“Accordingly, the derivate 25I-NBOMe has also been shown to decrease the density of post-mitotic cells in the rat hippocampus, indicating impaired neurogenesis in this brain region [37].”
BackgroundBiscoe, N., Bonson, A., Slavin, M., Busuttil, W., MacManus, D., Cox, A., & Murphy, D. (2023) · European Journal of Trauma & Dissociation · doi:10.1016/j.ejtd.2023.100359 · Cited by 8
Rougemont-Bücking, A., Guenot, F., Salamin, V., Gothuey, I., Duffour, C., King-Olivier, J., Girard, V., & Naudin, J. (2024) · European Journal of Trauma & Dissociation · doi:10.1016/j.ejtd.2024.100431 · Cited by 9
Ghaffarzadegan, R., Karimi, M., Hedayatjoo, B., Behnoud, H., Jasemi, E., Mohammadi, M., Roustaei, S., Razmi, A., & Vaseghi, S. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2428241 · Cited by 10
Psychedelic Medicines in Major Depression: Progress and Future Challenges
Bouso, J. C., Oña, G., SANTOS, R. G. D., & Hallak, J. E. C. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6044-0_26 · Cited by 10
Can Psychedelics be the Treatment for the Crisis in Psychopharmacology?Preprint
Oña, G., & Bouso, J. C. (2019) · Preprints.org · doi:10.20944/preprints201901.0249.v1 · Cited by 8
Mapping Psilocybin-Assisted Therapies: A Scoping ReviewPreprint
Shore, R., Ioudovski, P., Goldie, C. E., McKeown, S., & Dumont, É. C. (2019) · medRxiv · doi:10.1101/2019.12.04.19013896 · Cited by 10
“Smaller sub-perceptual doses would allow for more relaxed trial inclusion criteria, and could be possibly be used in the treatment of PTSD given the role of low-dose psilocybin in reducing fear response in laboratory animals (Catlow et al., 2013).”
BackgroundPsilocybin Combines Rapid Synaptogenic And Anti-Inflammatory Effects In VitroPreprint
Smedfors, G., Glotfelty, E. J., Kalani, N., Hjelle, C. P., Horntvedt, O., Wellfelt, K., Brodin, A., von Kieseritzky, F., Olson, L., & Karlsson, T. E. (2022) · Research Square · doi:10.21203/rs.3.rs-1321542/v1 · Cited by 8
The History, Legalization and Potentials of Psilocybin-Assisted Psychotherapy
Heilman, J. (2023) · Journal of Scientific Exploration · doi:10.31275/20222633 · Cited by 7
Irrmischer, M., Puxty, D. J., Yıldırım, B. O., Deijen, J. B., & Engelbregt, H. (2025) · Psychopharmacology · doi:10.1007/s00213-024-06733-3 · Cited by 9
The zebrafish for preclinical psilocybin research
Syed, O. A., Tsang, B., & Gerlai, R. T. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105381 · Cited by 9
Song, S., Kong, X., Sava, V., Cao, C., Acosta, S., Borlongan, C. V., & Sanchez‐Ramos, J. (2016) · Cell Transplantation · doi:10.3727/096368916x691114 · Cited by 7
Self-citationPsychedelic drugs as a long-needed innovation in psychiatryPreprint
Oña, G., & Bouso, J. C. (2020) · Qeios · doi:10.32388/t3em5e · Cited by 7
Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury
Plummer, Z., Allen, J., Brand, J., Mayo, L. M., Shultz, S. R., & Christie, B. R. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111448 · Cited by 6
Human pluripotent stem cells as a translational toolkit in psychedelic research in vitro
Salerno, J. A., & Rehen, S. K. (2024) · iScience · doi:10.1016/j.isci.2024.109631 · Cited by 7
Mushroom Toxins and Health Hazards Associated with Them
Singh, K., & Kumari, A. (2022) · Springer eBooks · doi:10.1007/978-981-19-2370-8_5 · Cited by 6
Wojtas, A., Herian, M., Maćkowiak, M., Solarz, A., Wawrzczak‐Bargieła, A., Bysiek, A., Noworyta, K., & Gołembiowska, K. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109713 · Cited by 6
Arinaga, M., Yamada, J., Maeda, S., Okamura, A., Oshima, Y., Zhang, L., Han, Y., Iinuma, K., & Jinno, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157519 · Cited by 6
“The anxiolytic properties of serotonergic compounds are supported by preclinical models [38] and clinical trials showing reduced anxiety and depression and improved quality of life in patients with cancer undergoing psilocybin therapy [39].”
Razidlo, J. A., Cataldo, N., & Wenthur, C. J. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00462 · Cited by 6
Multimodal Neuroimaging of the Effect of Serotonergic Psychedelics on the Brain
Frautschi, P. C., Singh, A. P., Stowe, N. A., & Yu, J. J. (2024) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8118 · Cited by 5
Psychedelics for military and Veteran communities? Research, practice, and policy considerations
Shore, R. (2023) · Journal of Military Veteran and Family Health · doi:10.3138/jmvfh.9.5.ed01 · Cited by 5
Effects of psilocybin on uncertain punishment learning
Jacobs, D. S., Bogachuk, A. P., Moing, C. L. L., & Moghaddam, B. (2024) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2024.107954 · Cited by 6
Advances in the pharmacotherapeutic management of post-traumatic stress disorder
Akhtar, A., & Sah, S. P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1935871 · Cited by 7
Zahid, Z., Sultan, Z. W., Krause, B. M., Wenthur, C. J., Pearce, R. A., & Banks, M. I. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0061 · Cited by 4
The immunomodulatory effects of psychedelics in Alzheimer’s disease-related dementia
Hosseini, A. M., Khaleghzadeh‐Ahangar, H., & Rahimi, A. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.11.062 · Cited by 4
Behavioural investigations of psilocybin in non-human animals 1962–2021: A scoping review
Shore, R., Dobson, K., Thomson, N., Barnim, N., Bergman, H. P., Rideout, K., McKeown, S., Olmstead, M. C., Goldie, C. E., & Dumont, É. C. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00364 · Cited by 5
Psilocybin to promote synaptogenesis in the brains of patients with mild cognitive impairment
Song, J., Kambari, Y., Amaev, A., Ueno, F., Carmona, E. T., Luca, V. D., Pollock, B. G., Flint, A. J., Husain, M. I., Graff‐Guerrero, A., et al. (2023) · Medical Hypotheses · doi:10.1016/j.mehy.2023.111068 · Cited by 5
Metadata
- Authors
- Catlow, B. J., Song, S., Paredes, D. A., Kirstein, C. L., & Sanchez-Ramos, J.
- Affiliations
- Lieber Institute for Brain Development (US)
- University of South Florida (US)
- Venue
- Experimental Brain Research
- Published
- 2013-06-02
- Volume
- 228
- Issue
- 4
- Pages
- 481-491
- ISSN
- 0014-4819 (ISSN-L)
- 1432-1106
- OpenAlex
- W2051271111
- Semantic Scholar
- f85018b1b5d6ec225219bde72260340ba25be97a
- Cited by
- 266
- References
- 70
- Citations by year
- 2026: 15 · 2025: 21 · 2024: 45 · 2023: 40 · 2022: 30 · 2021: 29 · 2020: 28 · 2019: 12 · 2018: 11 · 2017: 7 · 2016: 16 · 2015: 4 · 2014: 6 · 2013: 1
- FWCI
- 10.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Experimental Brain Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Keywords
- psilocybin, hippocampal neurogenesis, trace fear conditioning, fear extinction, 5-HT2A receptor agonists, ketanserin, serotonin, dentate gyrus, BrdU labeling, post-traumatic stress disorder, amygdala
- MeSH terms
- Animals, Conditioning, Psychological, Extinction, Psychological, Fear, Hallucinogens, Hippocampus, Male, Mice, Inbred C57BL, Psilocybin, Mice, Neurogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.